ReviewBiochimica et biophysica acta2008
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.
Review in Biochimica et biophysica acta, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 72 citations in OpenAlex.
- Exploring 14-3-3ζ: insights into its role in cancer mechanisms and future therapeutic applications.Hereditas · 2026Review
- The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia.Frontiers in oncology · 2021Review
- Review
- A Peroxidase Peroxiredoxin 1-Specific Redox Regulation of the Novel FOXO3 microRNA Target let-7.Antioxidants & redox signaling · 2018Article
- Resveratrol Role in Autoimmune Disease-A Mini-Review.Nutrients · 2017Review
- Forkhead transcription factors: new considerations for alzheimer's disease and dementia.Journal of translational science · 2016Article
- The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.BMC cancer · 2016Review
- DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.International journal of molecular sciences · 2015Review
- Article
- FoxO proteins in the nervous system.Analytical cellular pathology (Amsterdam) · 2015Review
- FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus.Current neurovascular research · 2015Review
- Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells.PloS one · 2014Article
- Critical physiological and pathological functions of Forkhead Box O tumor suppressors.Discoveries (Craiova, Romania) · 2013Review
- Article
- Targeting survival pathways in chronic myeloid leukaemia stem cells.British journal of pharmacology · 2013Review
- Signal transduction in the chronic leukemias: implications for targeted therapies.Current hematologic malignancy reports · 2013Review
- Article
- Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.Journal of blood medicine · 2012Article
- Computational identification and modeling of crosstalk between phosphorylation, O-β-glycosylation and methylation of FoxO3 and implications for cancer therapeutics.International journal of molecular sciences · 2012Article
- Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer.Frontiers in oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Numerous studies have revealed that the BCR-ABL oncoprotein abnormally engages a multitude of signaling pathways, some of which may be important for its leukemogenic properties. Central to this has been the determination that the tyrosine kinase function of BCR-ABL is mainly responsible for its transforming potential, and can be targeted with small molecule inhibitors, such as imatinib mesylate (Gleevec, STI-571). Despite this apparent success, the development of clinical resistance to imatinib therapy, and the inability of imatinib to eradicate BCR-ABL-positive malignant hematopoietic progenitors demand detailed investigations of additional effector pathways that can be targeted for CML treatment. The promotion of cellular survival via the suppression of apoptotic pathways is a fundamental characteristic of tumor cells that enables resistance to anti-cancer therapies. As substrates of survival kinases such as Akt, the FoxO family of transcription factors, particularly FoxO3a, has emerged as playing an important role in the cell cycle arrest and apoptosis of hematopoietic cells. This review will discuss our current understanding of BCR-ABL signaling with a focus on apoptotic suppressive mechanisms and alternative approaches to CML therapy, as well as the potential for FoxO transcription factors as novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.